"NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of " by Minesh Mehta

Menu

Skip to main content

All Publications

Minesh Mehta, Miami Cancer InstituteFollow

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Publication Date

2020

Content Type

Article

PubMed ID:

Additional Authors:

Additional authors and institutional affiliations

Citation

Cancer (2020) 126(12):2821-2828

Restricted

Available to BHSF community via local IP address or BHSF login.

Find in your library

COinS